<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04009434</url>
  </required_header>
  <id_info>
    <org_study_id>MITAVI</org_study_id>
    <nct_id>NCT04009434</nct_id>
  </id_info>
  <brief_title>Treatment of Concomitant Mitral Regurgitation by Mitral Valve Clipping in Patients With Successful Transcatheter Aortic Valve Implantation.</brief_title>
  <acronym>MITAVI</acronym>
  <official_title>Treatment of Concomitant Mitral Regurgitation by Mitral Valve Clipping in Patients With Successful Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KKS Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zentrum für Klinische Studien Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether patients after successful transfemoral transcatheter aortic valve&#xD;
      implantation (TAVI), who have concomitant, moderate to severe mitral regurgitation (MR)&#xD;
      benefit from an additional treatment of this valve disease as well.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death from any cause and heart failure hospitalization</measure>
    <time_frame>1 year</time_frame>
    <description>Composite endpoint of time to heart failure hospitalization or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death from any cause</measure>
    <time_frame>1, 2, 3, 4 years</time_frame>
    <description>Time from randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for mitral valve reintervention</measure>
    <time_frame>1, 2, 3, 4 years</time_frame>
    <description>Need for mitral valve reintervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral regurgitation severity</measure>
    <time_frame>1 year</time_frame>
    <description>Mitral regurgitation severity at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Test</measure>
    <time_frame>1 year</time_frame>
    <description>Change in 6 Minute Walk Test at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association Functional Class</measure>
    <time_frame>1, 3, 6 months and 1, 2, 3, 4 years</time_frame>
    <description>Course of New York Heart Association (NYHA) Functional Class at 1, 3, 6 months and 1, 2, 3, 4 years</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with AEs, SAEs.</measure>
    <time_frame>1, 2, 3, 4 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1162</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>TAVI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Transfemoral transcatheter aortic valve implantation plus optimal standard of care medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAVI/MitraClip</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfemoral transcatheter aortic valve implantation, mitral valve clipping plus optimal standard of care medical therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mitral Valve Clipping</intervention_name>
    <description>Patients receive treatment for mitral regurgitation with mitral valve clipping including standard drug therapy.</description>
    <arm_group_label>TAVI/MitraClip</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAVI</intervention_name>
    <description>Transfemoral transcatheter aortic valve implantation plus optimal standard of care therapy.</description>
    <arm_group_label>TAVI</arm_group_label>
    <arm_group_label>TAVI/MitraClip</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Planned transfemoral TAVI using an Edwards Sapien 3 Transcatheter Heart Valve (or&#xD;
             subsequent models)&#xD;
&#xD;
          -  Moderate to severe mitral regurgitation&#xD;
&#xD;
          -  Symptom status NYHA II-III&#xD;
&#xD;
          -  Treatment and compliance with optimal, individually-tailored guideline directed&#xD;
             medical therapy for heart failure for at least 30 days before inclusion&#xD;
&#xD;
          -  Age ≥ 18 and &lt; 90 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  MR mechanism/anatomy precluding MitraClip therapy&#xD;
&#xD;
          -  Groin blood vessels are not eligible for TAVI procedure&#xD;
&#xD;
          -  Massive or torrential tricuspid regurgitation&#xD;
&#xD;
          -  Patients who cannot tolerate procedural anticoagulation or post procedural&#xD;
             anti-platelet regimen.&#xD;
&#xD;
          -  Life expectancy &lt; 1 year due to non-cardiac conditions&#xD;
&#xD;
          -  LVEF ≤ 25%&#xD;
&#xD;
          -  Hypotension (systolic pressure &lt; 90 mmHg) or requirement of inotropic support or&#xD;
             mechanical hemodynamic support&#xD;
&#xD;
          -  Cardiomyopathy other than dilated cardiomyopathy&#xD;
&#xD;
          -  Fixed pulmonary artery systolic pressure &gt; 70 mm Hg&#xD;
&#xD;
          -  Any prior mitral valve surgery or transcatheter mitral valve procedure&#xD;
&#xD;
          -  Stroke or transient ischemic event within 6 months prior to randomization&#xD;
&#xD;
          -  Severe symptomatic carotid stenosis&#xD;
&#xD;
          -  Implant or revision of any rhythm management device (CRT or CRT-D) or implantable&#xD;
             cardioverter defibrillator within 90 days prior to randomization&#xD;
&#xD;
          -  Untreated clinically significant coronary artery disease requiring revascularization&#xD;
&#xD;
          -  Any percutaneous cardiac intervention or carotid surgery within the 30 days prior to&#xD;
             randomization, or any cardiac surgery within six months prior to randomization.&#xD;
&#xD;
          -  Need for any other cardiovascular surgery (other than MV or AV disease)&#xD;
&#xD;
          -  Echocardiographic evidence of intracardiac mass, thrombus, or vegetation&#xD;
&#xD;
          -  Active endocarditis or active infections requiring current antibiotic treatment&#xD;
&#xD;
          -  Any condition making it unlikely that the patient will be able to complete all&#xD;
             protocol procedures&#xD;
&#xD;
          -  Patient unable to provide written informed consent prior to study enrolment&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Women of child bearing potential&#xD;
&#xD;
          -  Current participation in any other interventional clinical trial&#xD;
&#xD;
          -  Patients under legal supervision or guardianship Patients placed in an institution by&#xD;
             official or court order&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Linke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universitaet Dresden, HEART CENTER</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Axel Linke, MD</last_name>
    <phone>+49 351 4501704</phone>
    <email>mitavi@mailbox.tu-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan Haussig, MD</last_name>
    <phone>+49 351 4501704</phone>
    <email>mitavi@mailbox.tu-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart-Center Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Haussig, MD</last_name>
      <phone>+493514501704</phone>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Stenosis</keyword>
  <keyword>Aortic Disease</keyword>
  <keyword>Transcatheter Aortic Valve Implantation</keyword>
  <keyword>Mitral Regurgitation</keyword>
  <keyword>Mitral Valve Regurgitation</keyword>
  <keyword>Mitral Disease</keyword>
  <keyword>Mitral valve clipping</keyword>
  <keyword>MitraClip</keyword>
  <keyword>Heart Valve Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>After publication of the primary objective, the data might be provided to interested scientists on request (e.g. for meta-analyses, health related registers or other scientific questions) in an anonymized way within five years, if the members of the MITAVI-trial group agree.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

